Continuous Glucose Monitor-Derived Glycemic Variability Indices Predict Subclinical Coronary Microvascular Dysfunction in Systemic Lupus Erythematosus 6–18 Months Before Stress Echocardiographic Abnormalities
Background
Patients with systemic lupus erythematosus (SLE) exhibit accelerated atherosclerosis and coronary microvascular dysfunction (CMD) disproportionate to traditional cardiovascular risk factors. Glycemic variability (GV), measurable via continuous glucose monitoring (CGM), reflects endothelial oxidative stress burden through recurrent glucose excursions that activate NADPH oxidase and suppress endothelial nitric oxide synthase. We hypothesize that CGM-derived GV indices — specifically coefficient of variation (%CV), mean amplitude of glycemic excursions (MAGE), and time-in-range (TIR) — capture subclinical endothelial injury in SLE patients and predict CMD progression 6–18 months before functional imaging detection.
Hypothesis
In non-diabetic SLE patients, a composite CGM-derived glycemic variability score (integrating %CV >36%, MAGE >3.0 mmol/L, and TIR <70%) measured over 14-day monitoring periods predicts coronary microvascular dysfunction — defined by coronary flow reserve (CFR) <2.5 on stress echocardiography — with >75% sensitivity and >70% specificity, 6–18 months before CFR deterioration becomes detectable.
Mechanism
Recurrent glycemic excursions → peroxynitrite-mediated endothelial glycocalyx degradation → reduced shear-stress mechanotransduction → impaired flow-mediated coronary dilation. In SLE, this pathway is amplified by: (1) type I interferon-driven endothelial progenitor cell exhaustion, (2) anti-endothelial cell antibody-mediated complement activation on microvasculature, and (3) immune complex deposition in coronary arterioles. The GV signal integrates these pathways into a single wearable-derived biomarker.
Testable Predictions
- Non-diabetic SLE patients with CGM %CV >36% will show 3-fold higher incidence of CMD at 12-month follow-up versus %CV ≤36% (HR >3.0, 95% CI excludes 1.0)
- Adding the GV composite score to the Framingham Risk Score improves C-statistic for CMD prediction by >0.08 (p <0.05)
- Serial 14-day CGM monitoring at 3-month intervals will demonstrate progressive GV deterioration preceding CFR decline by a median of 9 months (IQR 6–15)
- Anti-endothelial cell antibody titers will show positive correlation with MAGE (Spearman ρ >0.4) but not with HbA1c, confirming GV captures autoimmune-specific endothelial injury beyond average glycemia
Study Design
Prospective cohort, N=120 non-diabetic SLE patients (SLEDAI-2K ≥4), 18-month follow-up. CGM (Dexcom G7) 14-day wear every 3 months. Stress echocardiography with CFR measurement at baseline, 12, and 18 months. Covariates: SLEDAI-2K, prednisone dose, hydroxychloroquine use, lipid profile, hs-CRP, anti-endothelial cell antibodies. Primary analysis: time-dependent Cox regression with GV composite as time-varying covariate. Multiple testing correction: Benjamini-Hochberg FDR <0.05.
Limitations
- CGM accuracy in non-diabetic ranges may yield lower signal-to-noise ratio
- CMD diagnosis via stress echocardiography has operator-dependent variability (~10-15% inter-observer CFR disagreement)
- Confounding by corticosteroid-induced glucose excursions (partially addressed by prednisone dose covariate)
- Single-center design limits generalizability; would require multi-site validation
- 120 patients may be underpowered for subgroup analyses by SLE phenotype
Clinical Significance
If validated, this approach repurposes widely available consumer CGM technology as a non-invasive, continuous cardiovascular risk monitoring tool for SLE patients. Unlike periodic blood draws, CGM captures dynamic endothelial stress in real-time. Early CMD detection enables prophylactic intervention (intensified hydroxychloroquine, statin initiation, lifestyle modification) before irreversible microvascular remodeling. Cost: ~$75/sensor vs >$2,000 for stress echocardiography, enabling screening at scale in resource-limited settings.
LES AI • DeSci Rheumatology